These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Phase I trial of H65-RTA immunoconjugate in patients with cutaneous T-cell lymphoma. LeMaistre CF, Rosen S, Frankel A, Kornfeld S, Saria E, Meneghetti C, Drajesk J, Fishwild D, Scannon P, Byers V. Blood; 1991 Sep 01; 78(5):1173-82. PubMed ID: 1878584 [Abstract] [Full Text] [Related]
4. In vivo cytotoxic efficacy of immunotoxins prepared from anti-CD5 antibody linked to ricin A-chain. Rostaing-Capaillon O, Casellas P. Cancer Immunol Immunother; 1991 Sep 01; 34(1):24-30. PubMed ID: 1722138 [Abstract] [Full Text] [Related]
6. Inhibition of human T-cell tumor growth by T101-ricin A-chain in an athymic mouse model. Leonard JE, Johnson DE, Shawler DL, Dillman RO. Cancer Res; 1988 Sep 01; 48(17):4862-7. PubMed ID: 3261627 [Abstract] [Full Text] [Related]
8. Internalization and intracellular fate of anti-CD5 monoclonal antibody and anti-CD5 ricin A-chain immunotoxin in human leukemic T cells. Ravel S, Colombatti M, Casellas P. Blood; 1992 Mar 15; 79(6):1511-7. PubMed ID: 1372189 [Abstract] [Full Text] [Related]
9. The role of ricin B chain in the intracellular trafficking of anti-CD5 immunotoxins. Manske JM, Buchsbaum DJ, Vallera DA. J Immunol; 1989 Mar 01; 142(5):1755-66. PubMed ID: 2465347 [Abstract] [Full Text] [Related]
11. In vitro and in vivo enhancement of ricin-A chain immunotoxin activity by novel indolizine calcium channel blockers: delayed intracellular degradation linked to lipidosis induction. Jaffrézou JP, Levade T, Thurneyssen O, Chiron M, Bordier C, Attal M, Chatelain P, Laurent G. Cancer Res; 1992 Mar 01; 52(5):1352-9. PubMed ID: 1737397 [Abstract] [Full Text] [Related]
12. Investigation and prevention of artifactual staining in flow cytometric analyses of whole blood samples from patients treated with H65-RTA, an anti-CD5 monoclonal antibody conjugated to ricin A chain. Fishwild DM, Saria EA. J Immunol Methods; 1991 Nov 05; 144(1):27-34. PubMed ID: 1720441 [Abstract] [Full Text] [Related]
13. Cyclosporin A and cyclosporin SDZ PSC 833 enhance anti-CD5 ricin A-chain immunotoxins in human leukemic T cells. Jaffrézou JP, Sikic BI, Laurent G. Blood; 1994 Jan 15; 83(2):482-9. PubMed ID: 7506953 [Abstract] [Full Text] [Related]
14. A phase I study of T101-ricin A chain immunotoxin in refractory chronic lymphocytic leukemia. Hertler AA, Schlossman DM, Borowitz MJ, Laurent G, Jansen FK, Schmidt C, Frankel AE. J Biol Response Mod; 1988 Feb 15; 7(1):97-113. PubMed ID: 3373237 [Abstract] [Full Text] [Related]
15. Monensin in lipid emulsion for the potentiation of ricin A chain immunotoxins. Griffin T, Raso V. Cancer Res; 1991 Aug 15; 51(16):4316-22. PubMed ID: 1868454 [Abstract] [Full Text] [Related]
16. Parameters affecting tumor-specific delivery of anti-CD5 antibody-ricin A chain immunotoxins in vivo. Rostaing-Capaillon O, Casellas P. Cancer Res; 1990 May 15; 50(10):2909-16. PubMed ID: 1692250 [Abstract] [Full Text] [Related]
17. Efficacy of an anti-CD7-ricin A chain immunoconjugate in a novel murine model of human T-cell leukemia. Fishwild DM, Aberle S, Bernhard SL, Kung AH. Cancer Res; 1992 Jun 01; 52(11):3056-62. PubMed ID: 1375534 [Abstract] [Full Text] [Related]
19. Assessment of ligand effects in intracellular trafficking of ricin A chain using anti-ricin hybridomas. Kornfeld SB, Leonard JE, Mullen MD, Taetle R. Cancer Res; 1991 Mar 15; 51(6):1689-93. PubMed ID: 1998959 [Abstract] [Full Text] [Related]
20. Efficacy of an anti-CD5-ricin A chain immunoconjugate in an improved human peripheral blood lymphocyte--reconstituted severe combined immunodeficient mouse model. Kohn FR, Fishwild DM, Kung AH. Int J Immunopharmacol; 1993 Aug 15; 15(6):695-709. PubMed ID: 7691766 [Abstract] [Full Text] [Related] Page: [Next] [New Search]